Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
239 0
SM ISO690:2012
BOTHAMLEY, Graham Henry; LANGE, Christoph G.; ALBRECHT, Dirk; ANIBARRO, Luis; GOMEZ, Neus Altet; ANDERSEN, Aase Bengaard; AVSAR, Korkut; BALASANYANTS, Goar; BELTON, Moerida; GARCIA, Cristina Berastegui; BOGYI, Matthias; BRUCHFELD, Judith; CAMINERO, Jose Antonio; CHESOV, Dumitru; CHIAPPINI, Elena; CONFALONIERI, Marco; DEDICOAT, Martin John; LUIZA DE SOUZA-GALVAO, Maria; DUARTE, Raquel; DUDNYK, Andrii; DYRHOL-RIISE, Anne Ma A.; EISENHUT, Michael; ESTEBAN, Jaime; FLOE, Andreas; GARCIA-GARCIA, Jose Maria. Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study. In: Respiratory Medicine. 2017, nr. 132, pp. 68-75. ISSN 0954-6111.
10.1016/j.rmed.2017.09.007
EXPORT metadate:
Google Scholar
Crossref
CERIF
BibTeX
DataCite
Dublin Core
Respiratory Medicine
Numărul 132 / 2017 / ISSN 0954-6111

Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study


DOI: 10.1016/j.rmed.2017.09.007
Pag. 68-75

Bothamley Graham Henry12, Lange Christoph G.3, Albrecht Dirk4, Anibarro Luis5, Gomez Neus Altet6, Andersen Aase Bengaard7, Avsar Korkut8, Balasanyants Goar9, Belton Moerida10, Garcia Cristina Berastegui11, Bogyi Matthias12, Bruchfeld Judith13, Caminero Jose Antonio14, Chesov Dumitru15, Chiappini Elena16, Confalonieri Marco17, Dedicoat Martin John18, Luiza De Souza-Galvao Maria19, Duarte Raquel20, Dudnyk Andrii21, Dyrhol-Riise Anne Ma A.22, Eisenhut Michael23, Esteban Jaime24, Floe Andreas25, Garcia-Garcia Jose Maria26
 
1 Homerton University Hospital,
2 University Hospitals of Leicester NHS Trust,
3 Research Center Borstel,
4 Sunderby Hospital, Lulea,
5 Completo Hospitalario de Pontevedra,
6 Unidad de Tratamiento Directamente Observado Serveis Clinics, Barcelona,
7 Rigshospitalet,
8 Asklepios Fachklinik, München-Gauting,
9 Saint Petersburg Research Institute of Phthesiopulmonology,
10 Lewisham and Greenwich NHS Trust, London,
11 Servei Pneumologia, Hospital Universitari, Vall d'Hebron, Barcelona,
12 Wilhelminspital, Wien,
13 Karolinska University Hospital, Stockholm,
14 Hospital General Gran Canaria “Dr. Negrin”, Las Palmas,
15 ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
16 Meyer University Hospital, Florence,
17 University Hospital of Trieste,
18 Heart of England NHS Foundation Trust, Birmingham,
19 Unitat de Tuberculosis, Vall d'Hebron,
20 University of Porto,
21 National Pirogov Memorial Medical University, Vinnytsya,
22 Oslo University Hospital,
23 Luton and Dunstable University Hospital, Luton,
24 Department of Clinical Microbiology, IIS-Fundacion Jiminez Diaz, Madrid,
25 Aarhus University Hospital, Aarhus,
26 Hospital San Agustin, Avilés
 
Disponibil în IBN: 15 decembrie 2017


Rezumat

Aim Europe has the highest documented caseload and greatest increase in multidrug and extensively drug-resistant tuberculosis (M/XDR-TB) of all World Health Organization (WHO) regions. This survey examines how recommendations for M/XDR-TB management are being implemented. Methods TBNET is a pan-European clinical research collaboration for tuberculosis. An email survey of TBNET members collected data in relation to infection control, access to molecular tests and basic microbiology with drug sensitivity testing. Results 68/105 responses gave valid information and were from countries within the WHO European Region. Inpatient beds matched demand, but single rooms with negative pressure were only available in low incidence countries; ultraviolet decontamination was used in 5 sites, all with >10 patients with M/XDR-TB per year. Molecular tests for mutations associated with rifampicin resistance were widely available (88%), even in lower income and especially in high incidence countries. Molecular tests for other first line and second line drugs were less accessible (76 and 52% respectively). A third of physicians considered that drug susceptibility results were delayed by > 2 months. Conclusion Infection control for inpatients with M/XDR-TB remains a problem in high incidence countries. Rifampicin resistance is readily detected, but tests to plan regimens tailored to the drug susceptibilities of the strain of Mycobacterium tuberculosis are significantly delayed, allowing for further drug resistance to develop.

Cuvinte-cheie
Drug-resistance, Infection control,

Europe, PCR, tuberculosis